Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 9/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29563568 | 1.00 | RYR2 (0.51) | RYR2CA2CHKAKCNH2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL29563975 | 0.99 | RYR2 (0.50) | RYR2CA2CHKAKCNH2SIGMAR1 | |
| SCHEMBL26942227 | 0.87 | RYR2 (0.64) | RYR2KCNH2POLB | |
| SCHEMBL29563522 | 0.85 | RYR2 (0.51) | RYR2CA2CHKAKCNH2SIGMAR1 | |
| SCHEMBL24460447 | 0.85 | RYR2 (0.51) | RYR2CA2CHKAKCNH2SIGMAR1 | |
| SCHEMBL29563477 | 0.85 | RYR2 (0.51) | RYR2CA2CHKAKCNH2SIGMAR1 | |
| SCHEMBL24460437 | 0.85 | RYR2 (0.51) | RYR2CA2CHKAKCNH2SIGMAR1 | |
| SCHEMBL24460445 | 0.85 | RYR2 (0.54) | RYR2CA2CHKAKCNH2SIGMAR1 | |
| SCHEMBL24460348 | 0.82 | RYR2 (0.48) | RYR2CA2CHKAKCNH2SIGMAR1 | |
| SCHEMBL29563519 | 0.82 | RYR2 (0.48) | RYR2CA2CHKAKCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYCARMA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYCARMA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2022108945-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYR2, RYR1, ATP2A1 | RYR2 1/4885CA2 668/4885CHKA 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.